{
  "first_published_at": "2007-10-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079216", 
  "title": "Inhaled corticosteroids: pneumonia", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 319, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Inhaled corticosteroids: pneumonia</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Physicians should remain vigilant for pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with chronic obstructive pulmonary disease who are treated with inhaled products that contain steroids<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Long-acting beta<sub>2</sub> agonists (salmeterol or formoterol) and combination products that contain salmeterol with fluticasone (Seretide Accuhaler) or formoterol with budesonide (Symbicort Turbohaler) are indicated for the management of chronic obstructive pulmonary disease (COPD). Although inhaled corticosteroids are not indicated for monotherapy in COPD, treatment guidelines (including those issued by the Global initiative on Obstructive Lung Disease, GOLD)<cite>Global Strategy for the Diagnosis, Management and Prevention of COPD, <a href=\"http://www.goldcopd.org/\" target=\"_blank\">Global Initiative for Chronic Obstructive Lung Disease</a> (GOLD) 2006.</cite>recommend that inhaled steroids may be added to ongoing bronchodilator therapy in COPD management.</p><h2>The TORCH study</h2><p>TOwards a Revolution in COPD Health (TORCH)<cite>Calverley PM, et al. N Engl J Med 2007; <strong>356</strong>: 775&ndash;89</cite> compared Seretide Accuhaler (50 &micro;g salmeterol/500 &micro;g fluticasone twice a day), 50 &micro;g salmeterol twice a day, and 500 &micro;g fluticasone twice a day with placebo over a 3-year period. The primary endpoint was all-cause mortality within 3 years. The absolute risk for all-cause mortality was reduced by 2&middot;6% for Seretide compared with placebo, and was increased by 0&middot;8% for fluticasone compared with placebo (both nonsignificant).</p><p>The table summarises the absolute and relative risks of pneumonia for groups in the TORCH study:</p><p>&nbsp;</p><table class=\"standard\" style=\"WIDTH: 739px; HEIGHT: 274px\">\r\n\t\t\t<tbody>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td><strong>Placebo (n=1544)</strong></td>\r\n\t\t\t\t\t<td><strong>Salmeterol (n=1542)</strong></td>\r\n\t\t\t\t\t<td><strong>Fluticasone (n=1552)</strong></td>\r\n\t\t\t\t\t<td><strong>Seretide (n=1546)</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Number of events</td>\r\n\t\t\t\t\t<td>139 (9%)</td>\r\n\t\t\t\t\t<td>162 (11%)</td>\r\n\t\t\t\t\t<td>224 (14%)</td>\r\n\t\t\t\t\t<td>248 (16%)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Events per 1000 treatment-years</td>\r\n\t\t\t\t\t<td>51&middot;9</td>\r\n\t\t\t\t\t<td>51&middot;5</td>\r\n\t\t\t\t\t<td>84&middot;4</td>\r\n\t\t\t\t\t<td>87&middot;6</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Probability of event by 3 years* (95% CI)</td>\r\n\t\t\t\t\t<td>12&middot;3%<br>      (10&middot;4&ndash;14&middot;3)</td>\r\n\t\t\t\t\t<td>13&middot;3%<br>      (11&middot;4&ndash;15&middot;2)</td>\r\n\t\t\t\t\t<td>18&middot;3%<br>      (16&middot;1&ndash;20&middot;4)</td>\r\n\t\t\t\t\t<td>19&middot;6%<br>      (17&middot;4&ndash;21&middot;9)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td colspan=\"5\"><strong>Active treatment vs placebo</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Hazard ratio (95% CI)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td>1&middot;09<br>      (0&middot;87&ndash;1&middot;37)</td>\r\n\t\t\t\t\t<td>1&middot;53&dagger;<br>      (1&middot;24&ndash;1&middot;89)</td>\r\n\t\t\t\t\t<td>1&middot;64&dagger;<br>      (1&middot;33&ndash;2&middot;02)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td colspan=\"5\"><strong>Seretide vs components</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Hazard ratio (95%CI)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td>1&middot;51&dagger;<br>      (1&middot;24&ndash;1&middot;84)</td>\r\n\t\t\t\t\t<td>1&middot;07<br>      (0&middot;89&ndash;1&middot;28)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t</tr>\r\n\t\t\t</tbody></table><p><strong>Note</strong>: Log-Rank test stratified by smoking status. *Kaplan-Meier estimate. &dagger;p&lt;0&middot;001</p><p>In TORCH, older patients, patients with a lower body mass index (ie, &lt;25 kg/m<font class=\"super\">2</font>), and patients with very severe disease (FEV<font class=\"sub\">1</font>&lt;30% predicted) were at highest risk of pneumonia, irrespective of treatment.</p><h2>Other data</h2><p>A recent case-control study<cite>Ernst P, et al. Am J Respir Crit Care Med 2007; <strong>176</strong>: 162&ndash;66</cite> of 175 906 elderly patients with COPD suggested that current use of inhaled corticosteroids was associated with a significant increase of 70% in the frequency of hospitalisation for pneumonia compared with non-use in the last year. For patients with pneumonia who died within 30 days of hospitalisation, current use of inhaled corticosteroids significantly increased the frequency by 53%. The risks of hospitalisations for pneumonia and for subsequent death within 30 days were dose-dependent.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Physicians should remain vigilant for the development of pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with COPD who are treated with inhaled drugs that contain steroids because the clinical features of such infections and exacerbations frequently overlap</li>\r\n\t\t\t\t<li>Any patient with severe COPD who has had pneumonia during treatment with inhaled drugs that contain steroids should have their treatment reconsidered</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p><em>Article citation: Drug Safety Update October 2007; Vol 1, Issue 3: 5.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Long-acting beta<sub>2</sub> agonists (salmeterol or formoterol) and combination products that contain salmeterol with fluticasone (Seretide Accuhaler) or formoterol with budesonide (Symbicort Turbohaler) are indicated for the management of chronic obstructive pulmonary disease (COPD). Although inhaled corticosteroids are not indicated for monotherapy in COPD, treatment guidelines (including those issued by the Global initiative on Obstructive Lung Disease, GOLD)<cite>Global Strategy for the Diagnosis, Management and Prevention of COPD, <a href=\"http://www.goldcopd.org/\" target=\"_blank\">Global Initiative for Chronic Obstructive Lung Disease</a> (GOLD) 2006.</cite>recommend that inhaled steroids may be added to ongoing bronchodilator therapy in COPD management.</p><h2>The TORCH study</h2><p>TOwards a Revolution in COPD Health (TORCH)<cite>Calverley PM, et al. N Engl J Med 2007; <strong>356</strong>: 775&#8211;89</cite> compared Seretide Accuhaler (50 &#181;g salmeterol/500 &#181;g fluticasone twice a day), 50 &#181;g salmeterol twice a day, and 500 &#181;g fluticasone twice a day with placebo over a 3-year period. The primary endpoint was all-cause mortality within 3 years. The absolute risk for all-cause mortality was reduced by 2&#183;6% for Seretide compared with placebo, and was increased by 0&#183;8% for fluticasone compared with placebo (both nonsignificant).</p><p>The table summarises the absolute and relative risks of pneumonia for groups in the TORCH study:</p><p>&#160;</p><table class=\"standard\" style=\"WIDTH: 739px; HEIGHT: 274px\">\r\n\t\t\t<tbody>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td><strong>Placebo (n=1544)</strong></td>\r\n\t\t\t\t\t<td><strong>Salmeterol (n=1542)</strong></td>\r\n\t\t\t\t\t<td><strong>Fluticasone (n=1552)</strong></td>\r\n\t\t\t\t\t<td><strong>Seretide (n=1546)</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Number of events</td>\r\n\t\t\t\t\t<td>139 (9%)</td>\r\n\t\t\t\t\t<td>162 (11%)</td>\r\n\t\t\t\t\t<td>224 (14%)</td>\r\n\t\t\t\t\t<td>248 (16%)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Events per 1000 treatment-years</td>\r\n\t\t\t\t\t<td>51&#183;9</td>\r\n\t\t\t\t\t<td>51&#183;5</td>\r\n\t\t\t\t\t<td>84&#183;4</td>\r\n\t\t\t\t\t<td>87&#183;6</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Probability of event by 3 years* (95% CI)</td>\r\n\t\t\t\t\t<td>12&#183;3%<br>      (10&#183;4&#8211;14&#183;3)</td>\r\n\t\t\t\t\t<td>13&#183;3%<br>      (11&#183;4&#8211;15&#183;2)</td>\r\n\t\t\t\t\t<td>18&#183;3%<br>      (16&#183;1&#8211;20&#183;4)</td>\r\n\t\t\t\t\t<td>19&#183;6%<br>      (17&#183;4&#8211;21&#183;9)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td colspan=\"5\"><strong>Active treatment vs placebo</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Hazard ratio (95% CI)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td>1&#183;09<br>      (0&#183;87&#8211;1&#183;37)</td>\r\n\t\t\t\t\t<td>1&#183;53&#8224;<br>      (1&#183;24&#8211;1&#183;89)</td>\r\n\t\t\t\t\t<td>1&#183;64&#8224;<br>      (1&#183;33&#8211;2&#183;02)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td colspan=\"5\"><strong>Seretide vs components</strong></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Hazard ratio (95%CI)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t\t<td>1&#183;51&#8224;<br>      (1&#183;24&#8211;1&#183;84)</td>\r\n\t\t\t\t\t<td>1&#183;07<br>      (0&#183;89&#8211;1&#183;28)</td>\r\n\t\t\t\t\t<td></td>\r\n\t\t\t\t</tr>\r\n\t\t\t</tbody></table><p><strong>Note</strong>: Log-Rank test stratified by smoking status. *Kaplan-Meier estimate. &#8224;p&lt;0&#183;001</p><p>In TORCH, older patients, patients with a lower body mass index (ie, &lt;25 kg/m<font class=\"super\">2</font>), and patients with very severe disease (FEV<font class=\"sub\">1</font>&lt;30% predicted) were at highest risk of pneumonia, irrespective of treatment.</p><h2>Other data</h2><p>A recent case-control study<cite>Ernst P, et al. Am J Respir Crit Care Med 2007; <strong>176</strong>: 162&#8211;66</cite> of 175 906 elderly patients with COPD suggested that current use of inhaled corticosteroids was associated with a significant increase of 70% in the frequency of hospitalisation for pneumonia compared with non-use in the last year. For patients with pneumonia who died within 30 days of hospitalisation, current use of inhaled corticosteroids significantly increased the frequency by 53%. The risks of hospitalisations for pneumonia and for subsequent death within 30 days were dose-dependent.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Physicians should remain vigilant for the development of pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with COPD who are treated with inhaled drugs that contain steroids because the clinical features of such infections and exacerbations frequently overlap</li>\r\n\t\t\t\t<li>Any patient with severe COPD who has had pneumonia during treatment with inhaled drugs that contain steroids should have their treatment reconsidered</li>\r\n\t\t\t</ul></div><p>&#160;</p><p><em>Article citation: Drug Safety Update October 2007; Vol 1, Issue 3: 5.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-10-01", 
  "date_last_modified": "2010-08-23", 
  "_assets": [], 
  "_item_id": 319, 
  "summary": "Physicians should remain vigilant for pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with chronic obstructive pulmonary disease who are treated with inhaled products that contain steroids", 
  "body": "Article date: October 2007\n\nLong-acting beta2 agonists (salmeterol or formoterol) and combination products that contain salmeterol with fluticasone (Seretide Accuhaler) or formoterol with budesonide (Symbicort Turbohaler) are indicated for the management of chronic obstructive pulmonary disease (COPD). Although inhaled corticosteroids are not indicated for monotherapy in COPD, treatment guidelines (including those issued by the Global initiative on Obstructive Lung Disease, GOLD)[^1]recommend that inhaled steroids may be added to ongoing bronchodilator therapy in COPD management. \n\n## The TORCH study\n\nTOwards a Revolution in COPD Health (TORCH)[^2] compared Seretide Accuhaler (50 µg salmeterol/500 µg fluticasone twice a day), 50 µg salmeterol twice a day, and 500 µg fluticasone twice a day with placebo over a 3-year period. The primary endpoint was all-cause mortality within 3 years. The absolute risk for all-cause mortality was reduced by 2·6% for Seretide compared with placebo, and was increased by 0·8% for fluticasone compared with placebo (both nonsignificant). \n\nThe table summarises the absolute and relative risks of pneumonia for groups in the TORCH study:\n\n   \n  \n |   | Placebo (n=1544) |   | Salmeterol (n=1542) |   | Fluticasone (n=1552) |   | Seretide (n=1546) |   \nNumber of events |   | 139 (9%) |   | 162 (11%) |   | 224 (14%) |   | 248 (16%) |   \nEvents per 1000 treatment-years |   | 51·9 |   | 51·5 |   | 84·4 |   | 87·6 |   \nProbability of event by 3 years* (95% CI) |   | 12·3% (10·4–14·3) |   | 13·3% (11·4–15·2) |   | 18·3% (16·1–20·4) |   | 19·6% (17·4–21·9) |   \nActive treatment vs placebo |   \nHazard ratio (95% CI) |   |  |   | 1·09 (0·87–1·37) |   | 1·53† (1·24–1·89) |   | 1·64† (1·33–2·02) |   \nSeretide vs components |   \nHazard ratio (95%CI) |   |  |   | 1·51† (1·24–1·84) |   | 1·07 (0·89–1·28) |   |  | \n\nNote: Log-Rank test stratified by smoking status. *Kaplan-Meier estimate. †p<0·001\n\nIn TORCH, older patients, patients with a lower body mass index (ie, <25 kg/m2), and patients with very severe disease (FEV1<30% predicted) were at highest risk of pneumonia, irrespective of treatment.\n\n## Other data\n\nA recent case-control study[^3] of 175 906 elderly patients with COPD suggested that current use of inhaled corticosteroids was associated with a significant increase of 70% in the frequency of hospitalisation for pneumonia compared with non-use in the last year. For patients with pneumonia who died within 30 days of hospitalisation, current use of inhaled corticosteroids significantly increased the frequency by 53%. The risks of hospitalisations for pneumonia and for subsequent death within 30 days were dose-dependent. \n\nAdvice for healthcare professionals:  \n  \n  * Physicians should remain vigilant for the development of pneumonia and other infections of the lower respiratory tract (ie, bronchitis) in patients with COPD who are treated with inhaled drugs that contain steroids because the clinical features of such infections and exacerbations frequently overlap  \n  * Any patient with severe COPD who has had pneumonia during treatment with inhaled drugs that contain steroids should have their treatment reconsidered  \n  \n \n\nArticle citation: Drug Safety Update October 2007; Vol 1, Issue 3: 5.\n\n[^1]: Global Strategy for the Diagnosis, Management and Prevention of COPD, [Global Initiative for Chronic Obstructive Lung Disease](http://www.goldcopd.org/) (GOLD) 2006.\n\n[^2]: Calverley PM, et al. N Engl J Med 2007; 356: 775–89\n\n[^3]: Ernst P, et al. Am J Respir Crit Care Med 2007; 176: 162–66\n"
}